文献速递淋巴瘤

脑脊液MYD88 L265P突变与IL-10检测在原发中枢神经系统淋巴瘤中具有高特异性诊断价值:一项前瞻性研究结果

MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
PubMed 文献 · Br J Haematol · 2021-02-23

该前瞻性研究分析了初诊(n=36)和复发(n=27)原发中枢神经系统淋巴瘤(PCNSL)患者及162例对照者脑脊液中MYD88 L265P突变和IL-10的诊断灵敏度和特异性。结果显示,脑脊液中突变MYD88和高IL-10水平在初诊PCNSL患者中分别检出72%和88%,对照组仅1%;联合检测鉴别PCNSL的灵敏度和特异性分别为94%和98%,复发患者结果相似。

要点

  • 脑脊液突变MYD88和IL-10联合检测鉴别PCNSL灵敏度94%、特异性98%。
  • 初诊PCNSL脑脊液突变MYD88检出率72%,高IL-10检出率88%,对照仅1%。
  • 脑脊液突变MYD88与肿瘤组织突变状态一致率82%。

核心结论

  • 脑脊液中突变MYD88和高IL-10水平反映PCNSL组织的MYD88突变状态及IL-10合成,在初诊和复发时检测PCNSL均具有很高灵敏度和特异性。

研究设计与样本

  • 前瞻性研究纳入初诊PCNSL患者36例、复发PCNSL患者27例及对照162例(118例中枢神经系统疾病和44例中枢外淋巴瘤)。
  • 采用TaqMan法聚合酶链反应检测脑脊液突变MYD88,酶联免疫吸附试验检测脑脊液IL水平,RNAscope技术检测PCNSL活检组织IL-6和IL-10信使RNA。

主要发现

  • 17例PCNSL活检中15例(88%)检出突变MYD88,配对组织-脑脊液样本一致率82%。
  • 大多数PCNSL淋巴瘤B细胞中检出IL-10信使RNA,IL-6转录本表达可忽略。
  • 初诊PCNSL患者脑脊液突变MYD88检出率72%、高IL-10检出率88%,对照者仅1%;IL-6鉴别灵敏度和特异性低。
  • 联合分析MYD88和IL-10鉴别PCNSL的灵敏度和特异性分别为94%和98%,复发患者结果相似。

关键数值与推荐

  • 脑脊液突变MYD88联合高IL-10鉴别PCNSL:灵敏度94%,特异性98%。
  • 初诊PCNSL脑脊液突变MYD88检出率72%,高IL-10检出率88%,对照者检出率1%。
  • PCNSL活检突变MYD88检出率15/17(88%),配对组织-脑脊液一致率82%。

临床怎么用

  • 脑脊液突变MYD88和IL-10联合检测可作为PCNSL诊断的高灵敏度和高特异性生物标志物,适用于初诊和复发评估。
  • 对于不适合活检的病变患者,该标志物组合的应用价值有待进一步研究。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reaction. IL-6 and IL-10 messenger RNA (mRNA) was assessed on PCNSL biopsies using RNAscope technology. IL levels in CSF were assessed by enzyme-linked immunosorbent assay. Mut-MYD88 was detected in 15/17 (88%) PCNSL biopsies, with an 82% concordance in paired tissue-CSF samples. IL-10 mRNA was detected in lymphomatous B cells in most PCNSL; expression of IL-6 transcripts was negligible. In CSF samples, mut-MYD88 and high IL-10 levels were detected, respectively, in 72% and 88% of patients with newly diagnosed PCNSL and in 1% of controls; conversely, IL-6 showed a low discriminating sensitivity and specificity. Combined analysis of MYD88 and IL-10 exhibits a sensitivity and specificity to distinguish PCNSL of 94% and 98% respectively. Similar figures were recorded in patients with relapsed PCNSL. In conclusion, high detection rates of mut-MYD88 and IL-10 in CSF reflect, respectively, the MYD88 mutational status and synthesis of this IL in PCNSL tissue. These biomarkers exhibit a very high sensitivity and specificity in detecting PCNSL both at initial diagnosis and relapse. Implications of these findings in patients with lesions unsuitable for biopsy deserve to be investigated.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ferreri AJM, Calimeri T, Lopedote P, et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol. 2021. PMID: 33620087. doi:10.1111/bjh.17357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。